- Patients who completed the 13-week treatment of painful diabetic peripheral neuropathy
in Study A0081163.
- Patients must be able to understand and cooperate with study procedures and have
signed a written informed consent prior to entering the study
- Patients who experienced serious adverse events in the preceding study (A0081163) that
were determined by the investigator or the study sponsor to be causally related to the
- Patients exhibiting treatment non-compliance in the preceding study (A0081163)